Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
ImmunityBio enters the second week of October with the borrow market reversing course, retail attention spiking, and a short base that has barely shifted in a month, a combination that sharpens the setup ahead of the November 6 earnings date.
The most notable change from the prior two notes is what has happened to availability. After loosening through late September, reaching 17.9% by the final day of the month, the lending pool has tightened sharply again. Availability has fallen back to 10.9% as of October 8, down 31% on the week. That puts roughly one share available for every nine already borrowed. The 52-week minimum touched near zero in late August, so the borrow market is not back at its most extreme, but the direction has flipped. Cost to borrow edged up to 1.13%, a four-day high, though still well below the August spike above 2.4%. The short base itself remains essentially frozen: 125.4 million shares short, 12.7% of the free float, down just 0.02% on the week and 1.2% over the past month. The ORTEX short score holds at 82.4, placing IBRX in the second percentile of the universe on short score rank. Bears are not running, and they are not pressing. They are sitting on a position that now costs more to maintain as availability shrinks.
Options positioning has turned more defensive than at any point in the past year. The put/call ratio reached 0.41 on October 8, more than two standard deviations above its 20-day mean of 0.38, and is approaching its 52-week high of 0.42. That is a meaningful shift for a name where calls have consistently dominated. The move does not imply capitulation by bulls, PCR is still below 0.5, but the incremental flow is clearly toward protection rather than speculation. Against a backdrop of 22% price appreciation over the past month, some hedging into the print makes sense.
The analyst community remains uniformly bullish but there has been no new activity since June, when HC Wainwright reiterated its Buy at $15. The consensus sits at Buy with a mean target of $13.00, a 31% premium to the current price of $9.91. The bull case centres on ANKTIVA's biologic consistency across bladder cancer and NSCLC, a January 2027 PDUFA date for the supplemental BLA, and the potential to build out the bladder franchise beyond the current label. The bear case is more structural: a commercial ramp still in early stages, no path to GAAP profitability visible in the near term, and a valuation that rests on EPS assumptions for 2034. The EPS surprise factor score ranks in the 94th percentile, a strong beat history, but momentum scores over 30 and 90 days sit in the bottom decile, reflecting the gap between what analysts project and what the company currently earns.
Ownership concentration is the other structural feature here. Patrick Soon-Shiong filed a Schedule 13D amendment in August disclosing a 64.8% stake, down from 66.3% previously, across his personal holding and related entities including California Capital Equity and NantWorks. That trio accounts for roughly 61% of shares outstanding combined, leaving the effective free float considerably thinner than headline share counts suggest. BlackRock and State Street both added shares in the most recent reporting period, picking up 7.7 million and 3.7 million shares respectively. On the insider side, all recent open-market trades are under 10b5-1 plans: Director Cheryl Cohen sold shares in early October after exercising options at $2.98, and Director Barry Simon sold 25,000 shares at $10.75 on October 5. These are mechanical plan executions rather than discretionary signals. Net insider selling over 90 days is roughly $1.1 million, small relative to the concentrated founder position. Separately, Wikipedia views for IBRX are running more than two standard deviations above the stock's own 90-day baseline as of early October, a spike in retail attention that may partly explain the recent price strength relative to peers. EDIT and NTLA both gained on the week, up 12.7% and 4.0% respectively, while ABSI fell 16.8% and CRSP dropped 9.0%, making IBRX's 6.8% weekly gain look more stock-specific than sector-driven.
With 28 days to the next earnings print, the question is whether the re-tightening borrow market reflects new short demand at the current price level or simply a mechanical reduction in lendable supply, and whether the options market's shift toward protection is an early warning or routine hedging into a volatile biotech catalyst.
See the live data behind this article on ORTEX.
Open IBRX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
